VTYX - CIK 0001851194
The table below shows Ventyx Biosciences, Inc.'s cash flow statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Operating cash flow | -$130.87M | -$166.52M | -$98.77M | -$38.65M | -$6.20M |
| Capital expenditure | $241.00K | $514.00K | $275.00K | $262.00K | - |
| Investing cash flow | -$15.51M | $100.94M | -$74.93M | -$214.37M | - |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | - | - |
Ventyx Biosciences, Inc. reported operating cash flow of -$130.87M for fiscal year 2024. That is up 21.4% from -$166.52M in fiscal 2023. Over the 5 fiscal years shown, operating cash flow declined from -$6.20M (FY 2020) to -$130.87M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Financing cash flow | $122.11M | $53.33M | $167.77M | $323.55M | $6.13M |